Paeds Vivas · endocrinology-diabetes-and-growth
Osteoporosis and fragility fractures in children — branching viva
Branching viva on osteoporosis and fragility fractures in children: the ISCD definition that needs low bone mass plus a fragility fracture, the glucocorticoid-exposed and non-ambulant child, the foundation-first and bisphosphonate pathway with zoledronic acid first-line, and the safeguarding interface with non-accidental injury.
On this page & tools
Target exams
Opening: define and treat
The candidate opens by diagnosing osteoporosis. The defining move is that a vertebral compression fracture alone satisfies the ISCD definition of paediatric osteoporosis regardless of the bone density, so the T12 wedge makes the diagnosis even though the Z-score of minus 1.8 is not below the minus two threshold. The candidate states that the Z-score, never the T-score, is used in a child, and that a low Z-score alone is only low bone mass for age. The cause is secondary: glucocorticoid therapy compounded by immobility in Duchenne muscular dystrophy. [1] [3]
The treatment is the foundation first — correct calcium and vitamin D, review the glucocorticoid regimen, and maximise safe weight-bearing — then an intravenous bisphosphonate because a fracture is present. The candidate names zoledronic acid as the first-line agent, established by the phase three randomised trial in paediatric glucocorticoid-induced osteoporosis, and states that the child must be calcium and vitamin D replete before the first infusion to avoid symptomatic hypocalcaemia. [2] [4]
Branch 1: the low Z-score with no fracture
The examiner presents a child with a lumbar spine Z-score of minus 2.6 and no fracture history. The candidate refuses to label this osteoporosis: it is low bone mass for age, and the management is the foundation — calcium, vitamin D, weight-bearing, and treating any underlying cause — without a bisphosphonate. The candidate explains that the fracture, not the number, decides the drug, and that over-treating with a bisphosphonate exposes the child to the first-dose reaction and the hypocalcaemia risk without the diagnostic justification. [1] [4]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]Bishop N, Arundel P, Clark E, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 Pediatric Official Positions. J Clin Densitom, 2014.PMID 24631254
- [2]Ward LM, Choudhury A, Alos N, et al. Zoledronic Acid vs Placebo in Pediatric Glucocorticoid-induced Osteoporosis: A Randomized, Double-blind, Phase 3 Trial. J Clin Endocrinol Metab, 2021.PMID 34228102
- [3]LeBlanc CM, Ma J, Taljaard M, et al. Incident Vertebral Fractures and Risk Factors in the First Three Years Following Glucocorticoid Initiation Among Pediatric Patients With Rheumatic Disorders. J Bone Miner Res, 2015.PMID 25801315
- [4]Ciancia S, Högler W, Sakkers RJB, et al. Osteoporosis in children and adolescents: how to treat and monitor? Eur J Pediatr, 2023.PMID 36472650
- [5]Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health, 2018.PMID 29504223